ANI Pharmaceuticals has completed the acquisition of Novitium Pharma, a generic pharmaceutical company with its own line of such drugs. ANI will pay $89.5 million and 2,466,654 of its common stock for about $74 million. Novitium is also entitled to receive an additional $25 million if certain financial targets related to generic sales are achieved.